This October

the FDA window for CagriSema opened the same quarter Novo lost $30 billion defending it

In Q4 2026 — October through December — Novo Nordisk is awaiting an FDA decision on CagriSema, its once-weekly combination of cagrilintide and semaglutide. The NDA, filed December 18, 2025, is subject to a standard ten-month FDA review cycle. That window is here. On February 23, 2026, the Phase III REDEFINE 4 trial put CagriSema against Zepbound (tirzepatide 15 mg) in a head-to-head. BioPharma Dive covered the result: 23 percent weight loss for CagriSema at 84 weeks, against 25.5 percent for Zepbound. The trial primary goal was noninferiority. CagriSema did not achieve it. Novo Nordisk market cap dropped roughly $30 billion that day. The compound at the center of that decision is cagrilintide, the amylin analog that has been the largely unexamined half of the CagriSema story.

The actual molecule

cagrilintide is not another GLP-1 drug — it works through a completely different satiety circuit

Amylin is a 37-amino-acid hormone co-secreted with insulin from pancreatic beta cells after meals. It is not part of the GLP-1 axis. It acts primarily through the area postrema — a brainstem region outside the blood-brain barrier — and extends satiety signaling into hypothalamic circuits anatomically separate from those engaged by GLP-1 receptor agonists. The core biological claim behind cagrilintide is that it covers satiety territory semaglutide and tirzepatide do not. Cagrilintide is a fatty-acid modified, long-acting version of that amylin signaling biology, engineered for once-weekly dosing. Amylin-analog drug development is not new: pramlintide (Symlin) became FDA-approved in 2005 as an amylin mimetic for insulin-using patients, but required three-times-daily injections. PubMed indexes the amylin receptor pharmacology literature (https://pubmed.ncbi.nlm.nih.gov/?term=Cagrilintide) that underpins Novo's rationale. The question REDEFINE 4 answered is whether two distinct satiety circuits beat a single drug covering two receptor types through a different mechanism — and the answer was: not by enough to clear noninferiority against tirzepatide's GIP-plus-GLP-1 dual agonism.

What the market sold

the GLP-1-plus-amylin pitch moved faster than the head-to-head numbers arrived

Before REDEFINE 4, the CagriSema narrative was building toward a best-in-class designation. REIMAGINE 2 at the 2026 ADA Scientific Sessions showed the cagrilintide-semaglutide combination achieving 14.2 percent weight loss in patients with type 2 diabetes versus 7.3 percent with semaglutide alone — a result that made the additive-circuit argument look very strong. The online wellness narrative followed: two mechanisms beat one, the amylin circuit fills the gap GLP-1 drugs leave behind. Compounding pharmacies began preparing combinations of long-acting amylin analogs alongside GLP-1 receptor agonists, citing phase 2 combination data as rationale. The FDA's standing position on unapproved GLP-1-adjacent drug preparations (https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss) has not changed: trial data in investigational populations is not a compounding authorization, and cagrilintide remains investigational regardless of the NDA filing. The February 23 REDEFINE 4 result clarified the best-in-class argument. A 23-percent weight loss from a novel dual-mechanism approach is clinically meaningful. What it could not do is outrun the dual-receptor strategy that tirzepatide already represents.

What the data shows

real weight loss across four phase 3 trials — the head-to-head was the honest comparison

REDEFINE 1 in obesity produced 23 percent average weight loss. REIMAGINE 2 showed 14.2 percent versus 7.3 percent for semaglutide alone in type 2 diabetes, with greater HbA1c reduction. ClinicalTrials.gov tracks the full program at https://clinicaltrials.gov/search?term=Cagrilintide. Healio documented REDEFINE 4 at https://www.healio.com/news/endocrinology/20260223/zepbound-bests-cagrisema-for-weight-loss-among-adults-with-obesity: 23.0 versus 25.5 percent at 84 weeks, noninferiority not reached. That result does not mean cagrilintide is ineffective — it means the combination of amylin and GLP-1 signaling produces real weight loss, and that tirzepatide produces slightly more through dual GIP-GLP-1 agonism. Given that semaglutide alone achieves 15–17 percent in comparable trials, 23 percent is likely sufficient for approval on the labeled indication.

Early human — PeptideFactCheck stance

the evidence tier is early human — a Q4 FDA decision does not move it alone

Cagrilintide holds PeptideFactCheck's Early human evidence tier, and a pending FDA decision does not change that by itself. Early human means the evidence is not mature across all claims attaching to this compound in October 2026. That characterization remains accurate alongside REDEFINE 1 and REIMAGINE 2 — both are genuine human evidence, neither is an approved label. If the FDA approves CagriSema in Q4 2026, this profile will update to reflect that regulatory event for its specific labeled indication. An approval would not retroactively validate compounded amylin-combination preparations operating without an authorized formulation. It would confirm Novo Nordisk brought a once-weekly amylin analog to market, closing the half-open chapter pramlintide left since 2005. What to watch: the Q4 FDA decision, the REDEFINE 11 higher-dose trial with results expected H1 2027, and how an approved CagriSema label shapes the gray-market landscape for amylin-combination claims. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.